Articles tagged with: SLAMF7 Targeted Therapies
News»

The annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physicians from around the world, and featured a myriad of oral presentations, posters, and e-abstracts summarizing the results of new oncology- and hematology-related research.
Included in the research presented at the two meetings were more than 200 studies discussing new multiple myeloma-related findings.
In addition to the two large meetings held earlier this month, the International Myeloma Working Group (IMWG) …
News»

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a number of poster presentations related to multiple myeloma.
During “poster sessions” at conferences such as the ASCO meeting, research results are made available for review by meeting attendees in the form of posters, each of which summarizes the results of a single study. Each poster is typically about two feet high by three or four feet in length, and all posters during a session are displayed throughout a large conference hall.
Most of the myeloma-related …
News»

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.
Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treatment and care.
During the meeting, there will be presentations about all types of cancer, including many presentations focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be presented, in one form or another, in connection with the …
News, Opinion»

A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it is again …
News»

Saturday was the official first day of the 2014 American Society of Hematology (ASH) annual meeting. The day featured a wide range of interesting presentations about multiple myeloma.
Oral presentations about new treatments under development were given mid-day and were summarized in a Beacon ASH Daily Update published yesterday morning.
During Saturday evening, a poster session took place where important new research findings were summarized in posters displayed throughout two separate large conference halls.
The studies covered a variety of myeloma-related topics, ranging from new treatments being developed for myeloma, combination therapies …
News»

The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.
The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year. However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.
At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place. The presentations will summarize current research on a wide range of topics, including the biology of the disease …
Press Releases»
- This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma
- This new Phase I initiated by Bristol-Myers Squibb is the first combination trial of lirilumab in a hematological tumor type
Marseille, France (Press Release) - Innate Pharma SA (the "company" - euronext paris:FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that a new Phase I combination trial with lirilumab, a …